ASM 024
Alternative Names: ASM-024Latest Information Update: 24 Sep 2019
Price :
$50 *
At a glance
- Originator Asmacure
- Developer Odan Laboratories
- Class Antiasthmatics; Small molecules
- Mechanism of Action Muscarinic receptor modulators; Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic asthma; Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 24 Sep 2019 ASM 024 is still in phase II trials for inhalation for Asthma and chronic obstructive pulmonary disease (Odan website, September 2019)
- 19 Aug 2015 Odan Laboratories acquires Asmacure Ltee
- 10 Aug 2015 Phase-II development is ongoing for ASM 024 as a dry powder for inhalation for Asthma and chronic obstructive pulmonary disease